M.H.T. is supported by an Agency for Science Technology and Research&#8217;s Joint Council Office grant (1431AFG103), a National Medical Research Council grant (OFIRG/0017/2016), National Research Foundation grants (NRF2013-THE001-046 and NRF2013-THE001-093), a Ministry of Education Tier 1 grant (RG50/17 (S)), a startup grant from Nanyang Technological University, and funds for the International Genetically Engineering Machine (iGEM) competition from Nanyang Technological University.

<ol><li>Epinat, J. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+novel+engineered+meganuclease+induces+homologous+recombination+in+yeast+and+mammalian+cells%5BTitle%5D)+AND+%22Nucleic+Acids+Research%22%5BJournal%5D)">A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells.</a> Nucleic Acids Research. 31 (11), 2952-2962 (2003).</li>
<li>Arnould, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineered+I-CreI+derivatives+cleaving+sequences+from+the+human+XPC+gene+can+induce+highly+efficient+gene+correction+in+mammalian+cells%5BTitle%5D)+AND+%22Journal+of+Molecular+Biology%22%5BJournal%5D)">Engineered I-CreI derivatives cleaving sequences from the human XPC gene can induce highly efficient gene correction in mammalian cells.</a> Journal of Molecular Biology. 371 (1), 49-65 (2007).</li>
<li>Chapdelaine, P., Pichavant, C., Rousseau, J., Paques, F., Tremblay, J. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Meganucleases+can+restore+the+reading+frame+of+a+mutated+dystrophin%5BTitle%5D)+AND+%22Gene+Therapy%22%5BJournal%5D)">Meganucleases can restore the reading frame of a mutated dystrophin.</a> Gene Therapy. 17 (7), 846-858 (2010).</li>
<li>Carroll, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genome+engineering+with+zinc-finger+nucleases%5BTitle%5D)+AND+%22Genetics%22%5BJournal%5D)">Genome engineering with zinc-finger nucleases.</a> Genetics. 188 (4), 773-782 (2011).</li>
<li>Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., Gregory, P. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genome+editing+with+engineered+zinc+finger+nucleases%5BTitle%5D)+AND+%22Nature+Reviews+Genetics%22%5BJournal%5D)">Genome editing with engineered zinc finger nucleases.</a> Nature Reviews Genetics. 11 (9), 636-646 (2010).</li>
<li>Miller, J. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+TALE+nuclease+architecture+for+efficient+genome+editing%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">A TALE nuclease architecture for efficient genome editing.</a> Nature Biotechnology. 29 (2), 143-148 (2011).</li>
<li>Zhang, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+construction+of+sequence-specific+TAL+effectors+for+modulating+mammalian+transcription%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription.</a> Nature Biotechnology. 29 (2), 149-153 (2011).</li>
<li>Boch, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Breaking+the+code+of+DNA+binding+specificity+of+TAL-type+III+effectors%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Breaking the code of DNA binding specificity of TAL-type III effectors.</a> Science. 326 (5959), 1509-1512 (2009).</li>
<li>Moscou, M. J., Bogdanove, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+simple+cipher+governs+DNA+recognition+by+TAL+effectors%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">A simple cipher governs DNA recognition by TAL effectors.</a> Science. 326 (5959), 1501(2009).</li>
<li>Hsu, P. D., Lander, E. S., Zhang, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+and+applications+of+CRISPR-Cas9+for+genome+engineering%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Development and applications of CRISPR-Cas9 for genome engineering.</a> Cell. 157 (6), 1262-1278 (2014).</li>
<li>Sander, J. D., Joung, J. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cas+systems+for+editing%2C+regulating+and+targeting+genomes%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">CRISPR-Cas systems for editing, regulating and targeting genomes.</a> Nature Biotechnology. 32 (4), 347-355 (2014).</li>
<li>Jinek, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+programmable+dual-RNA-guided+DNA+endonuclease+in+adaptive+bacterial+immunity%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.</a> Science. 337 (6096), 816-821 (2012).</li>
<li>Nishimasu, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Crystal+structure+of+Cas9+in+complex+with+guide+RNA+and+target+DNA%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Crystal structure of Cas9 in complex with guide RNA and target DNA.</a> Cell. 156 (5), 935-949 (2014).</li>
<li>Yamano, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Crystal+Structure+of+Cpf1+in+Complex+with+Guide+RNA+and+Target+DNA%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA.</a> Cell. 165 (4), 949-962 (2016).</li>
<li>Swarts, D. C., Mosterd, C., van Passel, M. W., Brouns, S. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR+interference+directs+strand+specific+spacer+acquisition%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">CRISPR interference directs strand specific spacer acquisition.</a> PLoS One. 7 (4), e35888(2012).</li>
<li>Zetsche, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cpf1+is+a+single+RNA-guided+endonuclease+of+a+class+2+CRISPR-Cas+system%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.</a> Cell. 163 (3), 759-771 (2015).</li>
<li>Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., Doudna, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DNA+interrogation+by+the+CRISPR+RNA-guided+endonuclease+Cas9%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.</a> Nature. 507 (7490), 62-67 (2014).</li>
<li>Hu, J. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Evolved+Cas9+variants+with+broad+PAM+compatibility+and+high+DNA+specificity%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.</a> Nature. 556 (7699), 57-63 (2018).</li>
<li>Kleinstiver, B. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Broadening+the+targeting+range+of+Staphylococcus+aureus+CRISPR-Cas9+by+modifying+PAM+recognition%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition.</a> Nature Biotechnology. 33 (12), 1293-1298 (2015).</li>
<li>Kleinstiver, B. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineered+CRISPR-Cas9+nucleases+with+altered+PAM+specificities%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Engineered CRISPR-Cas9 nucleases with altered PAM specificities.</a> Nature. 523 (7561), 481-485 (2015).</li>
<li>Cong, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multiplex+genome+engineering+using+CRISPR%2FCas+systems%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Multiplex genome engineering using CRISPR/Cas systems.</a> Science. 339 (6121), 819-823 (2013).</li>
<li>Mali, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RNA-guided+human+genome+engineering+via+Cas9%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">RNA-guided human genome engineering via Cas9.</a> Science. 339 (6121), 823-826 (2013).</li>
<li>Jinek, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RNA-programmed+genome+editing+in+human+cells%5BTitle%5D)+AND+%22Elife%22%5BJournal%5D)">RNA-programmed genome editing in human cells.</a> Elife. 2, e00471(2013).</li>
<li>Cho, S. W., Kim, S., Kim, J. M., Kim, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeted+genome+engineering+in+human+cells+with+the+Cas9+RNA-guided+endonuclease%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease.</a> Nature Biotechnology. 31 (3), 230-232 (2013).</li>
<li>Wang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Systematic+evaluation+of+CRISPR-Cas+systems+reveals+design+principles+for+genome+editing+in+human+cells%5BTitle%5D)+AND+%22Genome+Biology%22%5BJournal%5D)">Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells.</a> Genome Biology. 19 (1), 62(2018).</li>
<li>Ran, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+genome+editing+using+Staphylococcus+aureus+Cas9%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">In vivo genome editing using Staphylococcus aureus Cas9.</a> Nature. 520 (7546), 186-191 (2015).</li>
<li>Hou, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+genome+engineering+in+human+pluripotent+stem+cells+using+Cas9+from+Neisseria+meningitidis%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+U+S+A%22%5BJournal%5D)">Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis.</a> Proceedings of the National Academy of Sciences U S A. 110 (39), 15644-15649 (2013).</li>
<li>Kim, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+genome+editing+with+a+small+Cas9+orthologue+derived+from+Campylobacter+jejuni%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni.</a> Nature Communications. 8, 14500(2017).</li>
<li>Edraki, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+Compact%2C+High-Accuracy+Cas9+with+a+Dinucleotide+PAM+for+In+Vivo+Genome+Editing%5BTitle%5D)+AND+%22Molecular+Cell%22%5BJournal%5D)">A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing.</a> Molecular Cell. , (2018).</li>
<li>Chatterjee, P., Jakimo, N., Jacobson, J. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Minimal+PAM+specificity+of+a+highly+similar+SpCas9+ortholog%5BTitle%5D)+AND+%22Science+Advances%22%5BJournal%5D)">Minimal PAM specificity of a highly similar SpCas9 ortholog.</a> Science Advances. 4 (10), (2018).</li>
<li>Muller, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Streptococcus+thermophilus+CRISPR-Cas9+Systems+Enable+Specific+Editing+of+the+Human+Genome%5BTitle%5D)+AND+%22Mol+Therapy%22%5BJournal%5D)">Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome.</a> Mol Therapy. 24 (3), 636-644 (2016).</li>
<li>Esvelt, K. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Orthogonal+Cas9+proteins+for+RNA-guided+gene+regulation+and+editing%5BTitle%5D)+AND+%22Nature+Methods%22%5BJournal%5D)">Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.</a> Nature Methods. 10 (11), 1116-1121 (2013).</li>
<li>Boratyn, G. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((BLAST%3A+a+more+efficient+report+with+usability+improvements%5BTitle%5D)+AND+%22Nucleic+Acids+Research%22%5BJournal%5D)">BLAST: a more efficient report with usability improvements.</a> Nucleic Acids Research. 41 (Web Server issue), W29-W33 (2013).</li>
<li>Hsu, P. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DNA+targeting+specificity+of+RNA-guided+Cas9+nucleases%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">DNA targeting specificity of RNA-guided Cas9 nucleases.</a> Nature Biotechnology. 31 (9), 827-832 (2013).</li>
<li>Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M., Valen, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CHOPCHOP%3A+a+CRISPR%2FCas9+and+TALEN+web+tool+for+genome+editing%5BTitle%5D)+AND+%22Nucleic+Acids+Research%22%5BJournal%5D)">CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing.</a> Nucleic Acids Research. 42 (Web Server issue), W401-W407 (2014).</li>
<li>Heigwer, F., Kerr, G., Boutros, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((E-CRISP%3A+fast+CRISPR+target+site+identification%5BTitle%5D)+AND+%22Nature+Methods%22%5BJournal%5D)">E-CRISP: fast CRISPR target site identification.</a> Nature Methods. 11 (2), 122-123 (2014).</li>
<li>Haeussler, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Evaluation+of+off-target+and+on-target+scoring+algorithms+and+integration+into+the+guide+RNA+selection+tool+CRISPOR%5BTitle%5D)+AND+%22Genome+Biology%22%5BJournal%5D)">Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR.</a> Genome Biology. 17 (1), 148(2016).</li>
<li>Bae, S., Park, J., Kim, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cas-OFFinder%3A+a+fast+and+versatile+algorithm+that+searches+for+potential+off-target+sites+of+Cas9+RNA-guided+endonucleases%5BTitle%5D)+AND+%22Bioinformatics%22%5BJournal%5D)">Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases.</a> Bioinformatics. 30 (10), 1473-1475 (2014).</li>
<li>Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., Corn, J. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhancing+homology-directed+genome+editing+by+catalytically+active+and+inactive+CRISPR-Cas9+using+asymmetric+donor+DNA%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA.</a> Nature Biotechnology. 34 (3), 339-344 (2016).</li>
<li>Richardson, C. D., Ray, G. J., Bray, N. L., Corn, J. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Non-homologous+DNA+increases+gene+disruption+efficiency+by+altering+DNA+repair+outcomes%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Non-homologous DNA increases gene disruption efficiency by altering DNA repair outcomes.</a> Nature Communications. 7, 12463(2016).</li>
<li>Gibson, D. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enzymatic+assembly+of+DNA+molecules+up+to+several+hundred+kilobases%5BTitle%5D)+AND+%22Nature+Methods%22%5BJournal%5D)">Enzymatic assembly of DNA molecules up to several hundred kilobases.</a> Nature Methods. 6 (5), 343-345 (2009).</li>
<li>Zhang, J. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+precise+knockin+with+a+double+cut+HDR+donor+after+CRISPR%2FCas9-mediated+double-stranded+DNA+cleavage%5BTitle%5D)+AND+%22Genome+Biology%22%5BJournal%5D)">Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage.</a> Genome Biology. 18 (1), 35(2017).</li>
<li>Ran, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genome+engineering+using+the+CRISPR-Cas9+system%5BTitle%5D)+AND+%22Nature+Protocols%22%5BJournal%5D)">Genome engineering using the CRISPR-Cas9 system.</a> Nature Protocols. 8 (11), 2281-2308 (2013).</li>
<li>Shmakov, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diversity+and+evolution+of+class+2+CRISPR-Cas+systems%5BTitle%5D)+AND+%22Nature+Reviews+Microbiology%22%5BJournal%5D)">Diversity and evolution of class 2 CRISPR-Cas systems.</a> Nature Reviews Microbiology. 15 (3), 169-182 (2017).</li>
<li>Moreno-Mateos, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cpf1+mediates+efficient+homology-directed+repair+and+temperature-controlled+genome+editing%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">CRISPR-Cpf1 mediates efficient homology-directed repair and temperature-controlled genome editing.</a> Nature Communications. 8 (1), 2024(2017).</li>
<li>Lin, S., Staahl, B. T., Alla, R. K., Doudna, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Enhanced+homology-directed+human+genome+engineering+by+controlled+timing+of+CRISPR%2FCas9+delivery%5BTitle%5D)+AND+%22Elife%22%5BJournal%5D)">Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery.</a> Elife. 3, e04766(2014).</li>
<li>Yang, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+scarless+human+stem+cell+genome+editing%5BTitle%5D)+AND+%22Nucleic+Acids+Research%22%5BJournal%5D)">Optimization of scarless human stem cell genome editing.</a> Nucleic Acids Research. 41 (19), 9049-9061 (2013).</li>
<li>Watanabe, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+ROCK+inhibitor+permits+survival+of+dissociated+human+embryonic+stem+cells%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">A ROCK inhibitor permits survival of dissociated human embryonic stem cells.</a> Nature Biotechnology. 25 (6), 681-686 (2007).</li>
</ol>

The authors do not have competing financial interests.

The CRISPR-Cas system is a powerful, revolutionary technology to engineer the genomes and transcriptomes of plants and animals. Numerous bacterial species have been found to contain CRISPR-Cas systems, which may potentially be adapted for genome and transcriptome engineering purposes44. Although the Cas9 endonuclease from Streptococcus pyogenes (SpCas9) was the first enzyme to be deployed successfully in human cells21,22,</su...

The ability to engineer the genome of any living organism has many biomedical and biotechnological applications, such as the correction of disease-causing mutations, construction of accurate cellular models for disease studies, or generation of agricultural crops with desirable traits. Since the turn of the century, various technologies have been developed for genome engineering in mammalian cells, including meganucleases1,2,3, zinc finger nucleases4,5, or transcription activator-like effector nucleases (TALENs)6,7,8,9. However, these earlier technologies are either difficult to program or tedious to assemble, thereby hampering their widespread adoption in research and the industry.
In recent years, the clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR-associated (Cas) system has emerged as a powerful new genome engineering technology10,11. Originally an adaptive immune system in bacteria, it has been successfully deployed for genome modification in plants and animals, including humans. A primary reason why CRISPR-Cas has gained so much popularity in such a short time is that the element that brings the key Cas endonuclease, such as Cas9 or Cas12a (also known as Cpf1), to the correct location in the genome is simply a short piece of chimeric single guide RNA (sgRNA), which is straightforward to design and cheap to synthesize. After being recruited to the target site, the Cas enzyme functions as a pair of molecular scissors and cleaves the bound DNA with its RuvC, HNH, or Nuc domains12,13,14. The resulting double stranded break (DSB) is subsequently repaired by the cells via either the non-homologous end joining (NHEJ) or homology-directed repair (HDR) pathway. In the absence of a repair template, the DSB is repaired by the error-prone NHEJ pathway, which can give rise to pseudo-random insertion or deletion of nucleotides (indels) at the cut site, potentially causing frameshift mutations in protein-coding genes. However, in the presence of a donor template that contains the desired DNA changes, the DSB is repaired by the high fidelity HDR pathway. Common types of donor templates include single-stranded oligonucleotides (ssODNs) and plasmids. The former is typically used if the intended DNA changes are small (for example, alteration of a single base pair), while the latter is typically used if one wishes to insert a relatively long sequence (for example, the coding sequence of a green fluorescent protein or GFP) into the target locus.
The endonuclease activity of the Cas protein requires the presence of a protospacer adjacent motif (PAM) at the target site15. The PAM of Cas9 is at the 3’ end of the protospacer, while the PAM of Cas12a (also called Cpf1) is at the 5’ end instead16. The Cas-guide RNA complex is unable to introduce a DSB if the PAM is absent17. Hence, the PAM places a constraint on the genomic locations where a particular Cas nuclease is able to cleave. Fortunately, Cas nucleases from different bacterial species typically exhibit different PAM requirements. Hence, by integrating various CRISPR-Cas systems into our engineering toolbox, we can expand the range of sites that may be targeted in a genome. Moreover, a natural Cas enzyme can be engineered or evolved to recognize alternative PAM sequences, further widening the scope of genomic targets accessible to manipulation18,19,20.
Although multiple CRISPR-Cas systems are available for genome engineering purposes, most users of the technology have relied mainly on the Cas9 nuclease from Streptococcus pyogenes (SpCas9) for multiple reasons. First, it requires a relatively simply NGG PAM, unlike many other Cas proteins that can only cleave in the presence of more complex PAMs. Second, it is the first Cas endonuclease to be successfully deployed in human cells21,22,23,24. Third, SpCas9 is by far the best characterized enzyme to date. If a researcher wishes to use another Cas nuclease, he or she would often be unclear about how best to design the experiment and how well other enzymes will perform in different biological contexts compared to SpCas9.
To provide clarity to the relative performance of different CRISPR-Cas systems, we have recently performed a systematic comparison of five Cas endonucleases – SpCas9, the Cas9 enzyme from Staphylococcus aureus (SaCas9), the Cas9 enzyme from Neisseria meningitidis (NmCas9), the Cas12a enzyme from Acidaminococcus sp. BV3L6 (AsCas12a), and the Cas12a enzyme from Lachnospiraceae bacterium ND2006 (LbCas12a)25. For a fair comparison, we evaluated the various Cas nucleases using the same set of target sites and other experimental conditions. The study also delineated design parameters for each CRISPR-Cas system, which would serve as a useful reference for users of the technology. Here, to better enable researchers to make use of the CRISPR-Cas system, we provide a step-by-step protocol for optimal genome engineering with different Cas9 and Cas12a enzymes (see Figure 1). The protocol not only includes experimental details but also important design considerations to maximize the likelihood of a successful genome engineering outcome in mammalian cells.
<img alt="CRISPR workflow diagram: sgRNA design, cloning, transduction, clone expansion, editing evaluation." class="xfigimg" src="/files/ftp_upload/59086/59086fig1.jpg" data-altupdatedat="1747911167000" data-alt="Figure 1"> 
Figure 1: An overview of the workflow to generate genome edited human cell lines. <a href="https://www.jove.com/files/ftp_upload/59086/59086fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

<table><tbody><tr><td>T4 Polynucleotide Kinase (PNK)</td><td>NEB</td><td>M0201</td><td></td></tr><tr><td>Shrimp Alkaline Phosphatase (rSAP)</td><td>NEB</td><td>M0371</td><td></td></tr><tr><td>Tris-Acetate-EDTA (TAE) Buffer, 50X</td><td>1st Base</td><td>BUF-3000-50X4L</td><td>Dilute to 1X before use. The 1X solution contains 40 mM Tris, 20 mM acetic acid, and 1 mM EDTA.</td></tr><tr><td>Tris-EDTA (TE) Buffer, 10X</td><td>1st Base</td><td>BUF-3020-10X4L</td><td>Dilute to 1X before use. The 1X solution contains 10 mM Tris (pH 8.0) and 1 mM EDTA.&amp;nbsp;</td></tr><tr><td>BbsI</td><td>NEB</td><td>R0539</td><td></td></tr><tr><td>BsmBI</td><td>NEB</td><td>R0580</td><td></td></tr><tr><td>T4 DNA Ligase</td><td>NEB</td><td>M0202</td><td>400,000 units/ml</td></tr><tr><td>Quick Ligation Kit</td><td>NEB</td><td>M2200</td><td>An alternative to T4 DNA Ligase.</td></tr><tr><td>Rapid DNA Ligation Kit</td><td>Thermo Scientific</td><td>K1423</td><td>An alternative to T4 DNA Ligase.</td></tr><tr><td>Zero Blunt TOPO PCR Cloning Kit</td><td>Thermo Scientific</td><td>451245</td><td>The salt solution comes with the TOPO vector in the kit.</td></tr><tr><td>NEBuilder HiFi DNA Assembly Master Mix</td><td>NEB</td><td>E2621L</td><td>Kit for Gibson assembly.</td></tr><tr><td>One Shot Stbl3 Chemically Competent E.Coli</td><td>Thermo Scientific</td><td>C737303</td><td></td></tr><tr><td>LB Broth (Lennox), powder</td><td>Sigma Aldrich</td><td>L3022</td><td>Reconstitute in ddH&lt;sub&gt;2&lt;/sub&gt;0, and autoclave before use</td></tr><tr><td>LB Broth with Agar (Lennox), powder</td><td>Sigma Aldrich</td><td>L2897</td><td>Reconstitute in ddH&lt;sub&gt;2&lt;/sub&gt;0, and autoclave before use</td></tr><tr><td>SOC media</td><td>-</td><td>-</td><td>2.5 mM KCl, 10 mM MgCl&lt;sub&gt;2&lt;/sub&gt;, 20 mM glucose in 1 L of LB Broth</td></tr><tr><td>Ampicillin (Sodium), USP Grade</td><td>Gold Biotechnology</td><td>A-301</td><td></td></tr><tr><td>REDiant 2X PCR Mastermix</td><td>1st Base</td><td>BIO-5185</td><td></td></tr><tr><td>Agarose</td><td>1st Base</td><td>BIO-1000</td><td></td></tr><tr><td>T7 Endonuclease I</td><td>NEB</td><td>M0302</td><td></td></tr><tr><td>Plasmid DNA Extraction Miniprep Kit</td><td>Favorgen</td><td>FAPDE 300</td><td></td></tr><tr><td>Dulbecco&#039;s Modified Eagle Medium (DMEM), High Glucose</td><td>Hyclone</td><td>SH30081.01</td><td>4.5 g/L Glucose, no L-glutamine, HEPES and Sodium Pyruvate</td></tr><tr><td>L-Glutamine, 200mM</td><td>Gibco</td><td>25030</td><td></td></tr><tr><td>Penicillin-Streptomycin, 10, 000U/mL</td><td>Gibco</td><td>15140</td><td></td></tr><tr><td>0.25% Trypsin-EDTA, 1X</td><td>Gibco</td><td>25200</td><td></td></tr><tr><td>Fetal Bovine Serum</td><td>Hyclone</td><td>SV30160</td><td>FBS is heat inactivated before use at 56 &lt;sup&gt;o&lt;/sup&gt;C for 30 min</td></tr><tr><td>Phosphate Buffered Saline, 1X</td><td>Gibco</td><td>20012</td><td></td></tr><tr><td>jetPRIME transfection reagent</td><td>Polyplus Transfection</td><td>114-75</td><td></td></tr><tr><td>QuickExtract DNA Extraction Solution, 1.0</td><td>Epicentre</td><td>LUCG-QE09050</td><td></td></tr><tr><td>ISOLATE II Genomic DNA Kit</td><td>Bioline</td><td>BIO-52067</td><td>An alternative to QuickExtract</td></tr><tr><td>Q5 High-Fidelity DNA Polymerase</td><td>NEB</td><td>M0491</td><td></td></tr><tr><td>Deoxynucleotide (dNTP) Solution Mix</td><td>NEB</td><td>N0447</td><td></td></tr><tr><td>6X DNA Loading Dye</td><td>Thermo Scientific</td><td>R0611</td><td>10 mM Tris-HCl (pH 7.6) 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA</td></tr><tr><td>Protease Inhibitor Cocktail, Set3</td><td>Merck</td><td>539134</td><td></td></tr><tr><td>Nitrocellulose membrane, 0.2&amp;micro;m</td><td>Bio-Rad</td><td>1620112</td><td></td></tr><tr><td>Tris-glycine-SDS buffer, 10X</td><td>Bio-Rad</td><td>1610772</td><td>Dilute to 1X before use. The 1x solution contains 25 mM Tris, 192 mM glycine, and 0.1% SDS.</td></tr><tr><td>Tris-glycine buffer, 10X</td><td>1st base</td><td>BUF-2020</td><td>Dilute to 1X before use. The 1x solution contains 25 mM Tris and 192 mM glycine.</td></tr><tr><td>Ponceau S solution</td><td>Sigma Aldrich</td><td>P7170</td><td></td></tr><tr><td>TBS, 20X</td><td>1st base</td><td>BUF-3030</td><td>Dilute to 1X before use. The 1x solution contains 25 mM Tris-HCl (pH 7.5) and 150 mM NaCl.</td></tr><tr><td>Tween 20</td><td>Sigma Aldrich</td><td>P9416</td><td></td></tr><tr><td>Skim Milk for immunoassay</td><td>Nacalai Tesque</td><td>31149-75</td><td></td></tr><tr><td>WesternBright Sirius-femtogram HRP</td><td>Advansta</td><td>K12043</td><td></td></tr><tr><td>Antibody for &amp;beta;-actin (C4)</td><td>Santa Cruz Biotechnology</td><td>sc-47778</td><td>Lot number: C0916</td></tr><tr><td>MiSeq system</td><td>Illumina</td><td>SY-410-1003</td><td></td></tr><tr><td>NanoDrop spectrophotometer</td><td>Thermo Scientific</td><td>ND-2000</td><td></td></tr><tr><td>Qubit fluorometer</td><td>Thermo Scientific</td><td>Q33226</td><td></td></tr><tr><td>EVOS FL Cell Imaging System</td><td>Thermo Scientific</td><td>AMF4300</td><td></td></tr><tr><td>CRISPR plasmid: pSpCas9(BB)-2A-GFP (PX458)</td><td>Addgene</td><td>48138</td><td>Single vector system: The gRNA is expressed from the same plasmid.</td></tr><tr><td>CRISPR plasmid: pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA</td><td>Addgene</td><td>61591</td><td>Single vector system: The gRNA is expressed from the same plasmid.</td></tr><tr><td>CRISPR plasmid: xCas9 3.7</td><td>Addgene</td><td>108379</td><td>Dual vector system: The gRNA is expressed from a different plasmid.</td></tr><tr><td>CRISPR plasmid: pX330-U6-Chimeric_BB-CBh-hSpCas9</td><td>Addgene</td><td>42230</td><td>Single vector system: The gRNA is expressed from the same plasmid.</td></tr><tr><td>CRISPR plasmid: hCas9</td><td>Addgene</td><td>41815</td><td>Dual vector system: The gRNA is expressed from a different plasmid.</td></tr><tr><td>CRISPR plasmid: eSpCas9(1.1)</td><td>Addgene</td><td>71814</td><td>Single vector system: The gRNA is expressed from the same plasmid.</td></tr><tr><td>CRISPR plasmid: VP12 (SpCas9-HF1)</td><td>Addgene</td><td>72247</td><td>Dual vector system: The gRNA is expressed from a different plasmid.</td></tr></tbody></table>

genome editing in mammalian cell lines using crispr-cas

The clustered regularly interspaced short palindromic repeats (CRISPR) system functions naturally in bacterial adaptive immunity, but has been successfully repurposed for genome engineering in many different living organisms. Most commonly, the wildtype CRISPR associated 9 (Cas9) or Cas12a endonuclease is used to cleave specific sites in the genome, after which the DNA double-stranded break is repaired via the non-homologous end joining (NHEJ) pathway or the homology-directed repair (HDR) pathway depending on whether a donor template is absent or present respectively. To date, CRISPR systems from different bacterial species have been shown to be capable of performing genome editing in mammalian cells. However, despite the apparent simplicity of the technology, multiple design parameters need to be considered, which often leave users perplexed about how best to carry out their genome editing experiments. Here, we describe a complete workflow from experimental design to identification of cell clones that carry desired DNA modifications, with the goal of facilitating successful execution of genome editing experiments in mammalian cell lines. We highlight key considerations for users to take note of, including the choice of CRISPR system, the spacer length, and the design of a single-stranded oligodeoxynucleotide (ssODN) donor template. We envision that this workflow will be useful for gene knockout studies, disease modeling efforts, or the generation of reporter cell lines.

To perform a genome editing experiment, a CRISPR plasmid expressing a sgRNA targeting the locus-of-interest needs to be cloned. First, the plasmid is digested with a restriction enzyme (typically a type IIs enzyme) to linearize it. It is recommended to resolve the digested product on a 1% agarose gel alongside an undigested plasmid to distinguish between a complete and partial digestion. As undigested plasmids are supercoiled, they tend to run faster than their linearized counterparts (see Figure 7</...

Watch this Scientific Journal Video about Genome Editing in Mammalian Cell Lines using CRISPR-Cas at JoVE.com

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

CRISPR-Cas is a powerful technology to engineer the complex genomes of plants and animals. Here, we detail a protocol to efficiently edit the human genome using different Cas endonucleases. We highlight important considerations and design parameters to optimize editing efficiency.

The clustered regularly interspaced short palindromic repeats (CRISPR) system functions naturally in bacterial adaptive immunity, but has been ...

genome-editing-in-mammalian-cell-lines-using-crispr-cas

Research

JoVE Journal

Genetics

21.5K Views.  Agency for Science Technology and Research. CRISPR-Cas is a powerful technology to engineer the complex genomes of plants and animals. Here, we detail a protocol to efficiently edit the human genome using different Cas endonucleases. We highlight important considerations and design parameters to optimize editing efficiency.

Video: Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells

The CRISPR/Cas9 genome engineering system has revolutionized biology by allowing for precise genome editing with little effort. Guided by a single guide RNA (sgRNA) that confers specificity, the Cas9 protein cleaves both DNA strands at the targeted locus. The DNA break can trigger either non-homologous end joining (NHEJ) or homology directed repair (HDR). NHEJ can introduce small deletions or insertions which lead to frame-shift mutations, while HDR allows for larger and more precise perturbations. Here, we present protocols for generating knockout cell lines by coupling established CRISPR/Cas9 methods with two options for downstream selection/screening. The NHEJ approach uses a single sgRNA cut site and selection-independent screening, where protein production is assessed by dot immunoblot in a high-throughput manner. The HDR approach uses two sgRNA cut sites that span the gene of interest. Together with a provided HDR template, this method can achieve deletion of tens of kb, aided by the inserted selectable resistance marker. The appropriate applications and advantages of each method are discussed.

Recent advances in the ability to genetically manipulate somatic cell lines hold great potential for basic and applied research. Here, we present two approaches for CRISPR/Cas9 generated knockout production and screening in mammalian cell lines, with and without the use of selectable markers.

The CRISPR/Cas9 genome engineering system has revolutionized biology by allowing for precise genome editing with little effort. Guided by a single guide ...

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

Combinatorial gene editing using CRISPR/Cas9 and single-stranded oligonucleotides is an effective strategy for the correction of single-base point mutations, which often are responsible for a variety of human inherited disorders. Using a well-established cell-based model system, the point mutation of a single-copy mutant eGFP gene integrated into HCT116 cells has been repaired using this combinatorial approach. The analysis of corrected and uncorrected cells reveals both the precision of gene editing and the development of genetic lesions, when indels are created in uncorrected cells in the DNA sequence surrounding the target site. Here, the specific methodology used to analyze this combinatorial approach to the gene editing of a point mutation, coupled with a detailed experimental strategy to measuring indel formation at the target site, is outlined. This protocol outlines a foundational approach and workflow for investigations aimed at developing CRISPR/Cas9-based gene editing for human therapy. The conclusion of this work is that on-site mutagenesis takes place as a result of CRISPR/Cas9 activity during the process of point mutation repair. This work puts in place a standardized methodology to identify the degree of mutagenesis, which should be an important and critical aspect of any approach destined for clinical implementation.

This protocol outlines the workflow of a CRISPR/Cas9-based gene editing system for the repair of point mutations in mammalian cells. Here, we use a combinatorial approach to gene editing with a detailed follow-on experimental strategy for measuring indel formation at the target site&#8212;in essence, analyzing onsite mutagenesis.

Combinatorial gene editing using CRISPR/Cas9 and single-stranded oligonucleotides is an effective strategy for the correction of single-base point ...

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

Genome-editing of human pluripotent stem cells (hPSCs) provides a genetically controlled and clinically relevant platform from which to understand human development and investigate the pathophysiology of disease. By employing site-specific nucleases (SSNs) for genome editing, the rapid derivation of new hPSC lines harboring specific genetic alterations in an otherwise isogenic setting becomes possible. Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 are the most commonly used SSNs. All of these nucleases function by introducing a double stranded DNA break at a specified site, thereby promoting precise gene editing at a genomic locus. SSN-meditated genome editing exploits two of the cell&#39;s endogenous DNA repair mechanisms, non-homologous end joining (NHEJ) and homology directed repair (HDR), to either introduce insertion/deletion mutations or alter the genome using a homologous repair template at the site of the double stranded break. Electroporation of hPSCs is an efficient means of transfecting SSNs and repair templates that incorporate transgenes such as fluorescent reporters and antibiotic resistance cassettes. After electroporation, it is possible to isolate only those hPSCs that incorporated the repair construct by selecting for antibiotic resistance. Mechanically separating hPSC colonies and confirming proper integration at the target site through genotyping allows for the isolation of correctly targeted and genetically homogeneous cell lines. The validity of this protocol is demonstrated here by using all three SSN platforms to incorporate EGFP and a puromycin resistance construct into the AAVS1 safe harbor locus in human pluripotent&#160;stem cells.

Genome editing of human pluripotent stem cells (hPSCs) can be done quickly and efficiently. Presented here is a robust experimental procedure to genetically engineer hPSCs as exemplified by editing the AAVS1 safe harbor locus to express EGFP and introduce antibiotic resistance.

Genome-editing of human pluripotent stem cells (hPSCs) provides a genetically controlled and clinically relevant platform from which to understand human ...

Developmental Biology

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

As a promising genome editing platform, the CRISPR/Cas9 system has great potential for efficient genetic manipulation, especially for targeted integration of transgenes. However, due to the low efficiency of homologous recombination (HR) and various indel mutations of non-homologous end joining (NHEJ)-based strategies in non-dividing cells, in vivo genome editing remains a great challenge. Here, we describe a homology-mediated end joining (HMEJ)-based CRISPR/Cas9 system for efficient in vivo precise targeted integration. In this system, the targeted genome and the donor vector containing homology arms (~800 bp) flanked by single guide RNA (sgRNA) target sequences are cleaved by CRISPR/Cas9. This HMEJ-based strategy achieves efficient transgene integration in mouse zygotes, as well as in hepatocytes in vivo. Moreover, a HMEJ-based strategy offers an efficient approach for correction of fumarylacetoacetate hydrolase (Fah) mutation in the hepatocytes and rescues Fah-deficiency induced liver failure mice. Taken together, focusing on targeted integration, this HMEJ-based strategy provides a promising tool for a variety of applications, including generation of genetically modified animal models and targeted gene therapies.

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) system provides a promising tool for genetic engineering, and opens up the possibility of targeted integration of transgenes. We describe a homology-mediated end joining (HMEJ)-based strategy for efficient DNA targeted integration in vivo and targeted gene therapies using CRISPR/Cas9.

As a promising genome editing platform, the CRISPR/Cas9 system has great potential for efficient genetic manipulation, especially for targeted integration ...

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Site-specific eukaryotic genome editing with CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) systems has quickly become a commonplace amongst researchers pursuing a wide variety of biological questions. Users most often employ the Cas9 protein derived from Streptococcus pyogenes in a complex with an easily reprogrammed guide RNA (gRNA). These components are introduced into cells, and through a base pairing with a complementary region of the double-stranded DNA (dsDNA) genome, the enzyme cleaves both strands to generate a double-strand break (DSB). Subsequent repair leads to either random insertion or deletion events (indels) or the incorporation of experimenter-provided DNA at the site of the break.
The use of a purified single-guide RNA and Cas9 protein, preassembled to form an RNP and delivered directly to cells, is a potent approach for achieving highly efficient gene editing. RNP editing particularly enhances the rate of gene insertion, an outcome that is often challenging to achieve. Compared to the delivery via a plasmid, the shorter persistence of the Cas9 RNP within the cell leads to fewer off-target events. 
Despite its advantages, many casual users of CRISPR gene editing are less familiar with this technique. To lower the barrier to entry, we outline detailed protocols for implementing the RNP strategy in a range of contexts, highlighting its distinct benefits and diverse applications. We cover editing in two types of primary human cells, T cells and hematopoietic stem/progenitor cells (HSPCs). We also show how Cas9 RNP editing enables the facile genetic manipulation of entire organisms, including the classic model roundworm Caenorhabditis elegans and the more recently introduced model crustacean, Parhyale hawaiensis.

Utilizing a preassembled Cas9 ribonucleoprotein complex (RNP) is a powerful method for precise, efficient genome editing. Here, we highlight its utility across a broad range of cells and organisms, including primary human cells and both classic and emerging model organisms.

Site-specific eukaryotic genome editing with CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) systems has ...

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Genome editing using the CRISPR-Cas system has vastly advanced the ability to precisely edit the genomes of various organisms. In the context of mammalian cells, this technology represents a novel means to perform genome-wide genetic screens for functional genomics studies. Libraries of guide RNAs (sgRNA) targeting all open reading frames permit the facile generation of thousands of genetic perturbations in a single pool of cells that can be screened for specific phenotypes to implicate gene function and cellular processes in an unbiased and systematic way. CRISPR-Cas screens provide researchers with a simple, efficient, and inexpensive method to uncover the genetic blueprints for cellular phenotypes. Furthermore, differential analysis of screens performed in various cell lines and from different cancer types can identify genes that are contextually essential in tumor cells, revealing potential targets for specific anticancer therapies. Performing genome-wide screens in human cells can be daunting, as this involves the handling of tens of millions of cells and requires analysis of large sets of data. The details of these screens, such as cell line characterization, CRISPR library considerations, and understanding the limitations and capabilities of CRISPR technology during analysis, are often overlooked. Provided here is a detailed protocol for the successful performance of pooled genome-wide CRISPR-Cas9 based screens.

CRISPR-Cas9 technology provides an efficient method to precisely edit the mammalian genome in any cell type and represents a novel means to perform genome-wide genetic screens. A detailed protocol discussing the steps required for the successful performance of pooled genome-wide CRISPR-Cas9 screens is provided here.

Genome editing using the CRISPR-Cas system has vastly advanced the ability to precisely edit the genomes of various organisms. In the context of mammalian ...

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

Human pluripotent stem cells offer a powerful system to study gene function and model specific mutations relevant to disease. The generation of precise heterozygous genetic modifications is challenging due to CRISPR-CAS9 mediated indel formation in the second allele. Here, we demonstrate a protocol to help overcome this difficulty by using two repair templates in which only one expresses the desired sequence change, while both templates contain silent mutations to prevent re-cutting and indel formation. This methodology is most advantageous for gene editing coding regions of DNA to generate isogenic control and mutant human stem cell lines for studying human disease and biology. In addition, optimization of transfection and screening methodologies have been performed to reduce labor and cost of a gene editing experiment. Overall, this protocol is widely applicable to many genome editing projects utilizing the human pluripotent stem cell model.

This protocol provides a method to facilitate the generation of defined heterozygous or homozygous nucleotide changes using CRISPR-CAS9 in human pluripotent stem cells.

Human pluripotent stem cells offer a powerful system to study gene function and model specific mutations relevant to disease. The generation of precise ...

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.

The bacterial Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Streptococcus pyogenes CRISPR-associated protein (Cas) system has been harnessed by researchers to study important biologically relevant problems. The unparalleled power of the CRISPR/Cas genome editing method allows researchers to precisely edit any locus of their choosing, thereby facilitating an increased understanding of gene function. Several methods for editing the C. elegans genome by CRISPR/Cas9 have been described previously. Here, we discuss and demonstrate a method which utilizes in vitro assembled ribonucleoprotein complexes and the dpy-10 co-CRISPR marker for screening. Specifically, in this article, we go through the step-by-step process of introducing premature stop codons into the C. elegans rbm-3.2 gene by homology-directed repair using this method of CRISPR/Cas9 editing. This relatively simple editing method can be used to study the function of any gene of interest and allows for the generation of homozygous-edited C. elegans by CRISPR/Cas9 editing&#160;in less than two weeks.

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.

The goal of this protocol is to enable seamless CRISPR/Cas9 editing of the C. elegans genome using assembled ribonucleoprotein complexes and the dpy-10 co-CRISPR marker for screening. This protocol can be used to make a variety of genetic modifications in C. elegans including insertions, deletions, gene replacements and codon substitutions.

The bacterial Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Streptococcus pyogenes CRISPR-associated protein (Cas) system has been ...

Efficient Genome Editing of Mice by CRISPR Electroporation of Zygotes

With exceptional efficiency, accuracy, and ease, the CRISPR/Cas9 system has significantly improved genome editing in cell culture and lab animal experiments. When generating animal models, the electroporation of zygotes offers higher efficiency, simplicity, cost, and throughput as an alternative to the gold standard method of microinjection. Electroporation is also gentler, with higher viability, and reliably delivers Cas9/single-guide RNA (sgRNA) ribonucleoproteins (RNPs) into the zygotes of common laboratory mouse strains (e.g., C57BL/6J and C57BL/6N) that approaches 100% delivery efficiency. This technique enables insertion/deletion (indels) mutations, point mutations, the deletion of whole genes or exons, and small insertions in the range of 100-200 bp to insert LoxP or short tags like FLAG, HA, or V5. While constantly being improved, here we present the current state of CRISPR-EZ in a protocol that includes sgRNA production through in vitro transcription, embryo processing, RNP assembly, electroporation, and the genotyping of preimplantation embryos. A graduate-level researcher with minimal experience manipulating embryos can obtain genetically edited embryos in less than 1 week using this protocol. Here, we offer a straightforward, low-cost, efficient, high-capacity method that could be used with mouse embryos.

Here, we describe a simple technique intended for the efficient generation of genetically modified mice called CRISPR RNP Electroporation of Zygotes (CRISPR-EZ). This method delivers editing reagents by electroporation into embryos at an efficiency approaching 100%. This protocol is effective for point mutations, small genomic insertions, and deletions in mammalian embryos.

With exceptional efficiency, accuracy, and ease, the CRISPR/Cas9 system has significantly improved genome editing in cell culture and lab animal ...

Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9

The prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system may be re-purposed for site-specific eukaryotic genome engineering. CRISPR/Cas9 is an inexpensive, facile, and efficient genome editing tool that allows genetic perturbation of genes and genetic elements. Here we present a simple methodology for CRISPR design, cloning, and delivery for the production of genomic deletions. In addition, we describe techniques for deletion, identification, and characterization. This strategy relies on cellular delivery of a pair of chimeric single guide RNAs (sgRNAs) to create two double strand breaks (DSBs) at a locus in order to delete the intervening DNA segment by non-homologous end joining (NHEJ) repair. Deletions have potential advantages as compared to single-site small indels given the efficiency of biallelic modification, ease of rapid identification by PCR, predictability of loss-of-function, and utility for the study of non-coding elements. This approach can be used for efficient loss-of-function studies of genes and genetic elements in mammalian cell lines.

CRISPR/Cas9 is a robust system to produce disruption of genes and genetic elements. Here we describe a protocol for the efficient creation of genomic deletions in mammalian cell lines using CRISPR/Cas9.

The prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 system may be re-purposed for site-specific ...

Genome Editing in Mammalian Cell Lines using CRISPR-Cas

Summary

Explore More Videos

Selection-dependent and Independent Generation of CRISPR/Cas9-mediated Gene Knockouts in Mammalian Cells

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells

Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Pooled CRISPR-Based Genetic Screens in Mammalian Cells

Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.

Efficient Genome Editing of Mice by CRISPR Electroporation of Zygotes

Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9